ReviewBMC medicine2017
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.
Review in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
189 citing papers in PubMed, 5 syntheses or guidelines pooled it, 374 citations in OpenAlex.
- Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis.Renal failure · 2025Pooled it
- Association between serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Chinese herbal medicine combined with western medicine for the treatment of type 2 diabetes mellitus with hyperuricemia: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Demographic, regional and temporal trends of hyperuricemia epidemics in mainland China from 2000 to 2019: a systematic review and meta-analysis.Global health action · 2021Pooled it
- Socioeconomic differences in hyperuricemia and gout: a systematic review and meta-analysis.Endocrine · 2020Pooled it
- Trial
- Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Gout Augments the Risk of Cardiovascular Disease in Patients With Psoriasis: A Population-Based Cohort Study.Frontiers in immunology · 2021Trial
- Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.EBioMedicine · 2018Trial
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HZBio1 in Chinese Healthy Subjects: A Randomized Phase 1a Study.Advances in therapy · 2026Article
- Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis.Drugs - real world outcomes · 2026Article
- The Dual Role of Exosomes in Gout: From Inflammatory Amplifiers to Therapeutic Regulators.Inflammation · 2026Review
- HIF-1α in CD4Journal of pharmaceutical analysis · 2026Article
- Association between remnant cholesterol level and gout in US adults.The Journal of international medical research · 2026Article
- Association Between the Korean Healthy Eating Index and Hyperuricemia Among Korean Adults.Journal of Korean medical science · 2026Article
- Personalized assessment of hyperuricemia probability in metabolic dysfunction-associated steatotic liver disease: construction and multicenter validation of a clinical nomogram.BMC gastroenterology · 2026Article
- Associations between cholesterol, high-density lipoprotein, and glucose index and hyperuricemia in patients with diabetes.BMC endocrine disorders · 2026Article
- Article
- Association of ABCG2 gene variants with urate levels in Mexican patients with type 2 diabetes and chronic kidney disease.Scientific reports · 2026Article
- Immunometabolic regulation in gouty arthritis: current evidence, mechanistic insights, and remaining challenges.Frontiers in immunology · 2026Review
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout, the most prevalent inflammatory arthritis worldwide, is associated with cardiovascular and renal diseases, and is an independent predictor of premature death. The frequencies of obesity, chronic kidney disease (CKD), hypertension, type 2 diabetes, dyslipidaemias, cardiac diseases (including coronary heart disease, heart failure and atrial fibrillation), stroke and peripheral arterial disease have been repeatedly shown to be increased in gout. Therefore, the screening and care of these comorbidities as well as of cardiovascular risk factors are of outmost importance in patients with gout. Comorbidities, especially CKD, and drugs prescribed for their treatment, also impact gout management. Numerous epidemiological studies have shown the association of asymptomatic hyperuricaemia with the above-mentioned diseases and cardiovascular risk factors. Animal studies have also produced a mechanistic approach to the vascular toxicity of soluble urate. However, causality remains uncertain because confounders, reverse causality or common etiological factors might explain the epidemiological results. Additionally, these uncertainties remain unsolved despite recent studies using Mendelian randomisation or therapeutic approaches. Thus, large randomised placebo-controlled trials are still needed to assess the benefits of treating asymptomatic hyperuricaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.